FoundationOne®CDx Indication Expansion
Various Solid Tumors
Key Facts
About Foundation Medicine
Foundation Medicine, founded in 2010 and headquartered in Cambridge, Massachusetts, is a commercial-stage diagnostics company and a global leader in comprehensive genomic profiling for oncology. Its flagship products, FoundationOne®CDx (tissue-based) and FoundationOne®Liquid CDx (blood-based), are FDA-approved companion diagnostics that analyze hundreds of genes to match advanced cancer patients with targeted therapies, immunotherapies, and clinical trials. As a wholly owned subsidiary of Roche since 2018, the company leverages its extensive genomic database, scientific expertise, and regulatory capabilities to support drug development for biopharma partners and integrate precision medicine into standard clinical workflow.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Guardant Infinity Biomarker Discovery | Guardant Health | Development/Commercial |
| Cytotoxic Oncology Generic | MSN Laboratories | Pre‑clinical |
| APCEDEN® | APAC Biotech | Approved |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| 177Lu‑BetaBart (RV‑01) | AtomVie Global Radiopharma | Phase 1/2a |
| BeiGene Oncology Portfolio | EVA Pharma | Phase 2/3 |
| Bevacizumab Biosimilar | Bio Usawa Biotechnology | Preclinical |
| PRIMO‑TB161‑001 | Primo Biotechnology | Preclinical |